Next Article in Journal
Involving the microRNA Targetome in Esophageal-Cancer Development and Behavior
Next Article in Special Issue
Impacts of Cancer on Platelet Production, Activation and Education and Mechanisms of Cancer-Associated Thrombosis
Previous Article in Journal
Identification of the Transcription Factor Relationships Associated with Androgen Deprivation Therapy Response and Metastatic Progression in Prostate Cancer
Previous Article in Special Issue
The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis
Article Menu
Issue 10 (October) cover image

Export Article

Open AccessReview
Cancers 2018, 10(10), 380;

Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment

School of Pharmacy and Biomedical Sciences, Curtin University, Perth 6100, Australia
Curtin Health Innovation Research Institute, Curtin University, Perth 6100, Australia
Fiona Stanley Hospital, Perth 6150, Australia
School of Medicine, Curtin University, Perth 6100, Australia
Author to whom correspondence should be addressed.
Received: 11 September 2018 / Revised: 4 October 2018 / Accepted: 7 October 2018 / Published: 11 October 2018
(This article belongs to the Special Issue The Role of Thrombosis and Haemostasis in Cancer)
PDF [996 KB, uploaded 11 October 2018]


Cancer-associated thrombosis is a major cause of mortality in cancer patients, the most common type being venous thromboembolism (VTE). Several risk factors for developing VTE also coexist with cancer patients, such as chemotherapy and immobilisation, contributing to the increased risk cancer patients have of developing VTE compared with non-cancer patients. Cancer cells are capable of activating the coagulation cascade and other prothrombotic properties of host cells, and many anticancer treatments themselves are being described as additional mechanisms for promoting VTE. This review will give an overview of the main thrombotic complications in cancer patients and outline the risk factors for cancer patients developing cancer-associated thrombosis, focusing on VTE as it is the most common complication observed in cancer patients. The multiple mechanisms involved in cancer-associated thrombosis, including the role of anticancer drugs, and a brief outline of the current treatment for cancer-associated thrombosis will also be discussed. View Full-Text
Keywords: venous thromboembolism; thrombosis; cancer venous thromboembolism; thrombosis; cancer

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Abdol Razak, N.B.; Jones, G.; Bhandari, M.; Berndt, M.C.; Metharom, P. Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment. Cancers 2018, 10, 380.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top